166188-11-0

166188-11-0 structure

Name: Tyrosinase (206-214) (human) acetate salt
Chemical Name: L-Alanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-tryptophyl-L-histidyl-N5-(diaminomethylene)-L-ornithyl-L-leucyl-L-phenylalanine
CAS Number: 166188-11-0
Molecular Formula: C₆₁H₈₃N₁₅O₁₀
Molecular Weight: 1186.406
Catalog: Signaling Pathways Metabolic Enzyme/Protease Tyrosinase
Create Date: 2018-07-05 07:35:40
Modify Date: 2024-01-08 18:16:56
Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL)[1].

Name	L-Alanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-tryptophyl-L-histidyl-N5-(diaminomethylene)-L-ornithyl-L-leucyl-L-phenylalanine
Synonyms	L-Phenylalanine, L-alanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-tryptophyl-L-histidyl-N5-(diaminomethylene)-L-ornithyl-L-leucyl- L-Alanyl-L-phenylalanyl-L-leucyl-L-prolyl-L-tryptophyl-L-histidyl-N5-(diaminomethylene)-L-ornithyl-L-leucyl-L-phenylalanine

Description	Tyrosinase (206-214), human (AFLPWHRLF), a 9-amino acid peptide, is a tyrosinase epitope. Tyrosinase (206-214), human can be recognized by HLA-A24 restricted, tumor-infiltrating lymphocytes (TIL)[1].
Related Catalog	Research Areas >> Cancer Research Areas >> Inflammation/Immunology Signaling Pathways >> Metabolic Enzyme/Protease >> Tyrosinase
In Vitro	Tyrosinase (206-214), human (AFLPWHRLF) can be used to generate melanoma-specific T cells for adoptive immunotherapy, as well as in peptide vaccines for HLA-A24+ melanoma[1].
In Vivo	Tyrosinase (206-214) is administered intranasally (i.n.; 45 µL; weekly for three weeks) into HLA-A24 transgenic (A24Tg) mice. Tyrosinase (206-214) shows an accumulation of murine CD3+ and CD8+ cells around the bronchioles. All A24Tg immunized with Tyrosinase (206-214) died after lethal A/HK483 infection[2].
References	[1]. X Kang, et al. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol. 1995 Aug 1;155(3):1343-8. [2]. Toru Ichihashi, et al. Cross-protective peptide vaccine against influenza A viruses developed in HLA-A*2402 human immunity model. PLoS One. 2011;6(9):e24626.